Skip to main content

Day: March 16, 2026

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Longer is Better’ Approach to Cardiovascular Risk Reduction – ANN ARBOR, Mich., March 16, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardiology (ACC)/American Heart Association (AHA) Multisociety Guideline on the...

Continue reading

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen’s transferrin-receptor targeting Enhanced Brain Delivery (EBD™) program Candidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcutaneous administration Lead clinical candidate IND targeted for mid-2027NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) —  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment...

Continue reading

Nova Winter Freight Haul Underway

Anchorage Alaska, March 16, 2026 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to announce that the mobilization of heavy equipment to the Estelle Project is underway via the Company’s winter snow road, approximately 150km from Willow. (Figure 1). Ideal winter conditions allowed snow road construction to commence in early December, which involved pre-packing snow, water-flooding for ice thickening at major river crossings, and minor brush clearing. This winter has delivered near perfect snow road conditions with exceptionally cold temperatures that are favorable for the construction of ice bridges over 1.5m (5ft) thick. These bridges are capable of supporting freight loads well over 100,000lb (45,000kg) while preserving a hard snowpack base. To watch a video of...

Continue reading

Bunker Hill on Track for June 2026 US Mine Restart Launches Exploration Program and Provides Project Update

KELLOGG, Idaho and VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR | OTCQB: BHLL), is pleased to provide an update on our progress toward the H1 2026 restart of the Bunker Hill Zinc-Silver-Lead Mine located in the prolific Silver Valley, Idaho, USA. HIGHLIGHTSSafety First: the project has achieved 40 months with no lost time injuries Project Progress: construction and commissioning is now 85% complete, and on track for the restart of operations and first concentrate production in June 2026 Processing Plant: the mills are turning, with commissioning advancing ahead of plan, complemented by the hiring of new team members Filter Plant: 100% of all mechanical installation completed, with contractors advancing the installation of piping and electrical...

Continue reading

Summit Royalties to Combine with Star Royalties to Create a Scaled, High-Growth Royalty Platform

TORONTO, March 16, 2026 (GLOBE NEWSWIRE) — Summit Royalties Ltd. (TSXV: SUM, OTCQB: SUMMF) (the “Company” or “Summit”) and Star Royalties Ltd. (TSXV: STRR, OTCQX: STRFF) (“Star”) are pleased to announce that they have entered into an arrangement agreement (the “Agreement”) pursuant to which, among other things, Summit has agreed to acquire all of the issued and outstanding common shares of Star by way of a court approved Plan of Arrangement under the Canada Business Corporations Act (the “Transaction”). Assuming completion of the Transaction, holders (“Star Shareholders”) of common shares of Star (“Star Shares”) are entitled to receive 0.360 (the “Exchange Ratio”) of a common share of Summit (each a “Summit Share”) in exchange...

Continue reading

KE Holdings Inc. Announces a Final Cash Dividend of US$0.3 Billion in Aggregate

BEIJING, March 16, 2026 (GLOBE NEWSWIRE) — KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE and HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced that its board of directors (the “Board”) approved a final cash dividend (the “Dividend”) of US$0.092 per ordinary share, or US$0.276 per ADS, to holders of ordinary shares and holders of ADSs of record as of the close of business on April 8, 2026, Beijing/Hong Kong Time and New York Time, respectively, payable in U.S. dollars. The aggregate amount of the Dividend to be paid will be approximately US$0.3 billion, which will be funded by cash surplus on the Company’s balance sheet. For holders of ordinary shares, in order to qualify for the Dividend, all valid documents for the transfer of shares accompanied by the...

Continue reading

Mawson Infrastructure Group Inc. Provides Update on Strategic Initiatives

Kaliste Saloom to Present at Emerging Growth Conference on April 2, 2026 MIDLAND, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (“Mawson” or the “Company”) today provided an update on its progress to deliver value to stockholders. Mawson has achieved a range of objectives over the past year, including regaining Nasdaq compliance, settling multiple lawsuits, which reduced the Company’s current liabilities by $19 million, and initiating a strategic pivot to artificial intelligence and high-performance computing. As these achievements were obtained over the course of fiscal 2025, the Mawson Board of Directors (the “Board”) formed a Strategic Transactions Committee to evaluate a range of alternatives to the Company, including potential M&A transactions, joint ventures and other opportunities. The Strategic...

Continue reading

Townsquare Reports Q4 and Year End Results; Maintains Current Dividend, Reflecting an 11% Yield Today

Digital Represents 55% of 2025 Total Net Revenue and 56% of 2025 Total Segment ProfitReduced Debt by $23 Million Since the February 2025 Refinancing PURCHASE, N.Y., March 16, 2026 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare”, the “Company,” “we,” “us” or “our”) announced today its financial results for the fourth quarter and year ended December 31, 2025. “I am pleased to share that Townsquare’s fourth quarter and year end results met our previously issued net revenue and Adjusted EBITDA guidance, reflecting our team’s hard work in the current environment. We are proud that the execution of our Digital First Local Media strategy allowed us to deliver excellent results for our clients, while also outperforming competitors and gaining market share,” commented Bill Wilson, Chief Executive Officer of Townsquare...

Continue reading

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01. All US Sites Treating Patients with Commercially Manufactured GP2 The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2. In 2024, the first of three commercial lots filling GP2 into vials for commercial sale or for clinical use was manufactured in a commercial facility....

Continue reading

Snowline Gold Announces Inclusion Into the GDXJ

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — SNOWLINE GOLD CORP. (TSX: SGD) (OTCQB: SNWGF) (the “Company” or “Snowline”) is pleased to announce that it has been included in the VanEck Junior Gold Miners ETF (“GDXJ”). The GDXJ is a widely followed exchange traded fund that provides investors with exposure to a global portfolio of junior and mid‑tier gold and silver mining, development and exploration companies. The rebalancing of the GDXJ will be effective as of market close March 20, 2026. “We are excited about Snowline’s upcoming addition to the GDXJ,” said Scott Berdahl, CEO & Director of Snowline. “Inclusion increases our visibility among passive and benchmark‑driven investors and may further enhance trading liquidity as our shareholder base continues to broaden.” ABOUT SNOWLINE GOLD CORP. Snowline Gold...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.